Following earnings, several big name tech stocks took a beating. We discuss Pandora, FireEye and HP and see what's caused their dips and debate whether they can earn their way back to "buy" status.

Oil's low prices have stuck around much longer than so many originally thought. Now, more than a year later, we're starting to see companies buckle under the pressure. Our energy team looks at the implications and the lesson to learn from these companies' demise.

Oil's low prices have stuck around much longer than so many originally thought. Now, more than a year later, we're starting to see companies buckle under the pressure. Our energy team looks at the implications and the lesson to learn from these companies' demise.

Exelixis has a newly approved melanoma drug hitting the market soon and Colorado voters will weigh in on universal healthcare in 2016.

Exelixis has a newly approved melanoma drug hitting the market soon and Colorado voters will weigh in on universal healthcare in 2016.

Traditional apparel retailers like Macy’s and Nordstrom have limped through 2015. What is driving weakness in the sector, and what should investors watch in the latest quarter?

Traditional apparel retailers like Macy’s and Nordstrom have limped through 2015. What is driving weakness in the sector, and what should investors watch in the latest quarter?

Tune in for discussions on the NYCB-Astoria Financial merger, New York Mellon Bank, and whether or not CEOs should live near HQ.

Tune in for discussions on the NYCB-Astoria Financial merger, New York Mellon Bank, and whether or not CEOs should live near HQ.

On this episode we talk earnings numbers, some cool stats from the conference call and check in on Facebook’s other big internet properties.